Hepatocellular carcinoma has a poor prognosis and is poorly responsive to systemic chemotherapy. Here we describe a case with unresectable hepatocellular carcinoma who achieved a complete response and has survived for more than 2 years, following treatment with a combination of adriamycin and etoposide (VP 16-213).
Get full access to this article
View all access options for this article.
References
1.
CavalliF., TschoppL., GerberA., SonntagR.W., RysselH.J., BrunnerK.W.: Therapieresultate mit VP 16-213 allein oder kombiniert mit 5-Fluorouracil beim Leberzellkarzinom (Hepatom).Schweiz Med. Wochenschr., 107: 1960–1964, 1977.
ChoiT.K., LeeN.W., WongJ.: Chemotherapy for advanced hepatocellular carcinoma: adriamycin versus quadruple chemotherapy.Cancer, 53: 401–405, 1984.
4.
FalksonG., MacIntyreJ., MoertelC.G., JohnsonL.A., ShermanR.C.: Primary liver cancer. An Eastern Cooperative Oncology Group Trial.Cancer, 54: 970–977, 1984.
5.
McBrideM.C.: Primary carcinoma of the liver.Surgery, 80: 322–327, 1976.
6.
MeliaW.M., JohnsonP.J., WilliamsR.: Induction of remission in hepatocellular carcinoma: A comparison of VP 16 with adriamycin.Cancer, 51: 206–210, 1983.
7.
OlwenyC.L.M., Katongole-MbiddeE., BahendekaS., OtimA., MugerwaJ.: Further experience in treating patients with hepatocellular carcinoma in Uganda.Cancer, 46: 2717–2722, 1980.
